CIK 0001088856 · Large accelerated filer
CORCEPT THERAPEUTICS INC
Sign in to watch- Ticker
- CORT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770487658
- Phone
- 650.688.8803
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,067,988
- in 15 filings, $36.6M under 10b5-1 plans
Net −$41,067,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −7,919 | $86.78 | $687K | 48,211 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −28,460 | $87.89 | $2.5M | 19,751 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −3,520 | $88.30 | $311K | 16,231 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −101 | $89.43 | $9K | 16,130 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −15,833 | 4,167 | ||
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −24,167 | 175,833 | ||
| 2026-07-07 | Guyer William Chief Development Officer | Option exercise 10b5-1 | +20,000 | $21.65 | $433K | 23,985 |
| 2026-07-07 | Guyer William Chief Development Officer | Sale 10b5-1 | −19,048 | $93.11 | $1.8M | 4,937 |
| 2026-07-07 | Guyer William Chief Development Officer | Sale 10b5-1 | −952 | $93.54 | $89K | 3,985 |
| 2026-07-07 | Guyer William Chief Development Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 130,000 | ||
| 2026-07-01 | Maduck Sean See Remarks | Option exercise 10b5-1 | +25,000 | $8.27 | $207K | 34,755 |
| 2026-07-01 | Maduck Sean See Remarks | Sale 10b5-1 | −11,024 | $87.33 | $963K | 23,731 |
| 2026-07-01 | Maduck Sean See Remarks | Sale 10b5-1 | −2,801 | $88.51 | $248K | 20,930 |
| 2026-07-01 | Maduck Sean See Remarks | Sale 10b5-1 | −11,175 | $89.31 | $998K | 9,755 |
| 2026-07-01 | Maduck Sean See Remarks | Option exercise · Stock option (right to buy) 10b5-1 | −25,000 | 116,986 | ||
| 2026-06-17 | MAHONEY DAVID L Director | Sale | −20,000 | $84.53 | $1.7M | 26,147 |
| 2026-06-16 | WILSON JAMES N Director | Sale 10b5-1 | −4,177 | $82.69 | $345K | 1,100,366 |
| 2026-06-16 | WILSON JAMES N Director | Sale 10b5-1 | −5,823 | $83.57 | $487K | 1,094,543 |
| 2026-06-15 | Mokari Atabak Chief Financial Officer | Option exercise 10b5-1 | +40,000 | $19.26 | $770K | 56,130 |
| 2026-06-15 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −9,434 | $80.02 | $755K | 46,696 |
Page 8 of 52 · 1,024 trades